Skip to content
Open access

Frailty After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Cross-Sectional Study of Incidence and Associated Factors

Oct 2026 · Journal of Multidisciplinary Healthcare · Vol 19, pp. 1-9 · 0 citations · 37 references
Medicine

TL;DR

A significant number of HCC patients could have frailty after TACE, and advanced age, female sex, poor nutrition, low Barthel Index, high SII, and low hemoglobin level were associated with frailty in these patients.

Abstract

Objective To evaluate the incidence of and factors associated with frailty in hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE), with the objective to inform future personalized managements. Methods In this cross-sectional study conducted from January to October 2025, HCC patients undergoing TACE at a tertiary hospital in Suzhou were selected by convenience sampling and completed a general information questionnaire. The Fried frailty phenotype, Nutritional Risk Screening 2002 tool, and Barthel Index for activities of daily living were comprehensively evaluated between postoperative days 1 and 4 following TACE. Factors associated with frailty after TACE were identified via univariate and multivariate logistic regression analyses. Results Among the 312 included patients, 87 (27.9%) patients and 225 (72.1%) patients were in the frailty and non-frailty groups, respectively. Univariate analysis revealed statistically significant differences in age, sex, nutritional risk, Barthel Index, systemic immune-inflammatory index (SII), and hemoglobin level between the two groups (P<0.05). Multivariate logistic regression analysis identified that age, sex, nutritional risk, Barthel Index, SII, and hemoglobin level were associated with frailty after TACE, with odds ratios of 1.060, 4.199, 6.870, 0.954, 1.001, and 0.980, respectively (all P<0.05). Conclusion A significant number of HCC patients could have frailty after TACE. Advanced age, female sex, poor nutrition, low Barthel Index, high SII, and low hemoglobin level were associated with frailty in these patients. Further prospective trials are required to identify modifiable variables and evaluate interventions to prevent or reduce frailty in HCC patients undergoing TACE.

Read PDF

Similar papers

Open access Oct 2026

CLINICAL AND TECHNICAL OUTCOMES OF TRANSARTERIAL CHEMOEMBOLIZATION (TACE) FOR HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER EXPERIENCE

Elevated AFP and PIVKA-II levels, multifocal involvement, and tumor size ≥ 5 cm were associated with advanced disease and high technical success and acceptable short-term safety of transarterial chemoembolization demonstrated high technical success and acceptable short-term safety.

A. Kozhamkul, A. Berkinbay, Y. Abilkhanov et al. · 0 citations
Sep 2026

Impact of adjuvant transarterial chemoembolization on survival following hepatectomy for subcapsular hepatocellular carcinoma: A propensity score-matched study.

BACKGROUND Subcapsular hepatocellular carcinoma (HCC) is prone to postoperative recurrence, possibly related to tumor cell dissemination during surgery. Despite this high-risk feature, the role of routine postoperative adjuvant transarterial chemoembolization (TACE) remains controversial. This study evaluated adjuvant...

Q. Kong, Hao-Jia Wang, Jia-Hui Yang et al. · 0 citations
Open access Oct 2026

Network analysis of core symptom changes in hepatocellular carcinoma survivors after transarterial chemoembolization: A longitudinal study

Objective The aims of this study were to explore the longitudinal trajectories of core symptoms in survivors with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) and to analyze their associations with health-related quality of life (HRQoL) and unmet supportive care needs. Methods This longit...

Su-Ping Wang, Xiu-Yan Wang, Ni Jiang et al. · 0 citations
Open access Sep 2026

Transarterial Radioembolization Versus Chemoembolization for Unresectable Large Single Hepatocellular Carcinoma

In patients with unresectable large solitary HCCs, TARE was associated with longer OS, improved local tumor control, and fewer serious adverse events than TACE, however, the survival advantage should be interpreted with caution.

M. Lee, Minuk Kim, Jayoun Kim et al. · 0 citations
Open access Oct 2026

Preoperative Frailty and Risk of Post-ERCP Pancreatitis in Older Adults with Choledocholithiasis

Background Frailty is increasingly considered when evaluating surgical risk in older adults. However, evidence regarding whether frailty contributes to the risk of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in elderly patients is limited. Objective We aimed to evaluate whether preoperative...

Fan Zhang, Min Zeng, Y. Wan et al. · 0 citations
Sep 2026

Prediction of the Efficacy of PA-TACE in Patients with Clearly Defined Hepatocellular Carcinoma by Imaging Combined with Serology: A Retrospective Cohort Study with a Two-Center Follow-Up of up to 12 Years.

The suggested dual-center nomogram shows excellent practical relevance in assessing the effectiveness of PA-TACE and improving postoperative care techniques, and integrates CT radiomics and serological markers, with overall survival as the major outcome.

Jin-Yi Liu, Qiang Xu, Qian Song et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.